Navigation Links
Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting

REDWOOD CITY, Calif., May 21 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from three studies at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2009, at the Orange County Convention Center in Orlando, Florida. The company currently markets the widely-adopted Oncotype DX(R) breast cancer test, which is clinically validated to predict the likelihood of recurrence and chemotherapy benefit in early-stage breast cancer patients, and plans to launch a test for colon cancer in early 2010 based on positive results from the QUASAR validation study being presented at ASCO.

    Presentation details are as follows:

    Colon Cancer
        -- Saturday, May 30, 2009, 3 p.m. ET
           Abstract # 4000
           Oral presentation: "A quantitative multi-gene RT-PCR assay for
           prediction of recurrence in stage II colon cancer:  Selection of
           the genes in 4 large studies and results of the independent,
           prospectively-designed QUASAR validation study" Presenter: David
           Kerr, M.D., DSc, professor of cancer medicine at the University of
           Oxford Location: Level 2, West Hall D2

    In addition, an archived webcast of the advance presscast highlighting the
    QUASAR colon cancer validation study is available on ASCO's Web site at

    Breast Cancer
        -- Sunday, May 31, 2009, 4:30 p.m. ET
           Abstract # 500
           Oral presentation: "Genotypic characterization of phenotypically
           defined triple-negative breast cancer"
           Presenter: Joseph A. Sparano, M.D., professor of medicine and
           women's health at Albert Einstein College of Medicine and director
           of the Breast Evaluation Center of Montefiore-Einstein Cancer
           Center in the Bronx, New York
           Location: Level 2, West Hall D2

        -- Monday, June 1, 2009, 1-5:00 p.m. ET
           Abstract # 549
           Poster presentation: "Molecular characterization of male breast
           cancer by standardized quantitative RT-PCR analysis: First large
           genomic study of 347 male breast cancers compared to 82,434 female
           breast cancers"
           Presenter: Steve Shak, M.D., chief medical officer, Genomic Health
           Poster board: A17
           Location: Level 2, West Hall C

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX(R) breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the applicability of clinical study results to actual outcomes and the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
(Date:11/29/2015)... ... 2015 , ... Effective immediately, every single IguanaMed scrub style will be available ... is offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” ... at a discounted price. , IguanaMed’s mission is to outfit every healer ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 6th by ... University of British Columbia suggested that laws requiring bicyclists to wear helmets may not ... of the reason for the controversial conclusion is that, while helmets have certainly prevented ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
Breaking Medicine Technology: